What is the Orchid Pharma Ltd share price today?

The share price of NSE:ORCHPHARMA-EQ on 01 Oct 2026 (as of 15:04:28 IST) is ₹987.6.

What is the NSE:ORCHPHARMA-EQ 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:ORCHPHARMA-EQ 52 week high low range shows a high of ₹1143.5 and a low of ₹480.

What is the Orchid Pharma Ltd market cap?

As on 01 Oct 2026, Orchid Pharma Ltd market cap is ₹59636700000.

What is the shareholding pattern of Orchid Pharma Ltd Stock?

The shareholding pattern of Orchid Pharma Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 69.84% Foreign Institutional Investors (FII): 0.8% Domestic Institutional Investors (DII): 0.82% Mutual Funds: 19.93% Retail & Others: 8.61% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Orchid Pharma Ltd?

The Price-to-Earnings (PE) ratio of Orchid Pharma Ltd is 688.168, and the Price-to-Book (PB) ratio is 0.4816, as on 01 Oct 2026.

Orchid Pharma Share Price

945.25-14.70 (-1.53%)

+29.79% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-1.53%

1 Week

-3.93%

1 Month

-5.76%

3 Month

-12.39%

6 Month

+66.01%

YTD

+24.55%

1 Year

+29.79%

5 Year

+117.70%

10 Year

Max

+5411.66%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

940.00

923.70

541.65

480.00

High

968.30

998.75

1143.50

About

Orchid Pharma (Orchid) established as an export-oriented unit (EOU) is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research manufacturing Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

ZYDUSLIFENSE

LAURUSLABSNSE

CIPLANSE

DRREDDYNSE

MANKINDNSE

AUROPHARMANSE

LUPINNSE

ORCHPHARMANSE

LTP

1W Low

1W High

Market cap (₹)

1746.4-13.6 (-0.77%)

1725.50

1776.60

4,24,466Cr

9023-317 (-3.39%)

8937.50

9431.50

2,46,222Cr

4580-76.9 (-1.65%)

4551.80

4682

1,76,301Cr

1124.7+7.2 (0.64%)

1107.30

1150.90

1,12,818Cr

2036.9+0.3 (0.01%)

2007.80

2069.20

1,10,823Cr

1314.6+13.6 (1.05%)

1300.20

1333.30

1,07,447Cr

1216+19 (1.59%)

1196.90

1250.70

1,03,471Cr

2335-33.5 (-1.41%)

2317.50

2426.80

97,850Cr

1662.9-30.1 (-1.78%)

1654.10

1715

96,836Cr

1953.2-3.3 (-0.17%)

1925.70

1964.90

89,629Cr

945.25-38.7 (-3.93%)

940

998.75

5,748Cr

Orchid Pharma Share Price

945.25-14.70 (-1.53%)

+29.79% past 1 Year

Financial overview

Compounded Sales Growth

10 years4%

5 years22%

3 years23%

Last year-12%

Compounded Profit Growth

10 years-

5 years-

3 years-40%

Last year-92%

Stock Price CAGR

10 years-

5 years17%

3 years25%

1 year30%

Return on Equity

10 years-22%

5 years4%

3 years7%

Last year1%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
4%	22%	23%	-12%
-	-	-40%	-92%
-	17%	25%	30%
-22%	4%	7%	1%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

ZYDUSLIFE

LAURUSLABS

CIPLA

DRREDDY

MANKIND

AUROPHARMA

LUPIN

ORCHPHARMA

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,746.4	₹424466 Cr	35.09	12.07	62.82	₹11479 Cr
9,023	₹246222 Cr	84.18	34.04	128.41	₹2568 Cr
4,580	₹176301 Cr	80.83	16.72	97.06	₹2163 Cr
1,124.7	₹112818 Cr	25	9.42	62.53	₹5040 Cr
2,036.9	₹110823 Cr	101.36	6.8	29.25	₹889 Cr
1,314.6	₹107447 Cr	31.88	9.77	57.87	₹3879 Cr
1,216	₹103471 Cr	32.11	5.32	63.99	₹4196 Cr
2,335	₹97850 Cr	47.9	13.75	71.08	₹1913 Cr
1,662.9	₹96836 Cr	26.08	17.95	96.84	₹3505 Cr
1,953.2	₹89629 Cr	16.21	30.95	154.35	₹5333 Cr
945.25	₹5748 Cr	663.29	0.54	7.75	₹10 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020	Jun 2020	Mar 2020	Dec 2019	Sep 2019	Jun 2019	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Jun 2008	Jun 2007	Jun 2006
₹304 Cr	₹238 Cr	₹207 Cr	₹194 Cr	₹263 Cr	₹237 Cr	₹217 Cr	₹223 Cr	₹244 Cr	₹217 Cr	₹221 Cr	₹199 Cr	₹183 Cr	₹210 Cr	₹160 Cr	₹165 Cr	₹131 Cr	₹178 Cr	₹161 Cr	₹128 Cr	₹92 Cr	₹120 Cr	₹103 Cr	₹109 Cr	₹119 Cr	₹112 Cr	₹129 Cr	₹132 Cr	₹135 Cr	₹497 Cr	₹479 Cr	₹360 Cr	₹336 Cr	₹310 Cr	₹252 Cr	₹213 Cr
₹2 Cr	₹7 Cr	₹6 Cr	₹11 Cr	₹12 Cr	₹4 Cr	₹8 Cr	₹8 Cr	₹8 Cr	₹13 Cr	₹8 Cr	₹8 Cr	₹2 Cr	₹2 Cr	₹9 Cr	₹6 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹11 Cr	₹2 Cr	₹93 L	₹1 Cr	₹6 Cr	₹7 Cr	₹7 Cr	₹5 Cr	₹0	₹3 L	₹0	₹1 L	₹18 Cr	₹53 Cr	₹75 L
₹306 Cr	₹245 Cr	₹213 Cr	₹204 Cr	₹275 Cr	₹241 Cr	₹226 Cr	₹230 Cr	₹252 Cr	₹230 Cr	₹228 Cr	₹207 Cr	₹185 Cr	₹212 Cr	₹169 Cr	₹171 Cr	₹134 Cr	₹180 Cr	₹164 Cr	₹130 Cr	₹95 Cr	₹131 Cr	₹105 Cr	₹109 Cr	₹120 Cr	₹117 Cr	₹136 Cr	₹138 Cr	₹141 Cr	₹497 Cr	₹479 Cr	₹360 Cr	₹336 Cr	₹328 Cr	₹305 Cr	₹213 Cr
₹301 Cr	₹220 Cr	₹215 Cr	₹204 Cr	₹279 Cr	₹218 Cr	₹200 Cr	₹201 Cr	₹220 Cr	₹197 Cr	₹194 Cr	₹183 Cr	₹168 Cr	₹177 Cr	₹154 Cr	₹165 Cr	₹140 Cr	₹179 Cr	₹168 Cr	₹137 Cr	₹113 Cr	₹122 Cr	₹137 Cr	₹121 Cr	₹130 Cr	₹155 Cr	₹161 Cr	₹164 Cr	₹179 Cr	₹406 Cr	₹380 Cr	₹328 Cr	₹268 Cr	₹273 Cr	₹215 Cr	₹177 Cr
₹16 Cr	₹34 Cr	₹7 Cr	₹9 Cr	₹6 Cr	₹32 Cr	₹35 Cr	₹38 Cr	₹40 Cr	₹42 Cr	₹43 Cr	₹32 Cr	₹24 Cr	₹41 Cr	₹23 Cr	₹24 Cr	₹15 Cr	₹28 Cr	₹16 Cr	₹13 Cr	₹3 Cr	₹29 Cr	-₹3 Cr	₹19 Cr	₹21 Cr	-₹7 Cr	₹7 Cr	₹6 Cr	-₹7 Cr	₹129 Cr	₹131 Cr	₹72 Cr	₹101 Cr	₹87 Cr	₹114 Cr	₹56 Cr
₹2 Cr	₹3 Cr	₹3 Cr	₹4 Cr	₹2 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹4 Cr	₹4 Cr	₹6 Cr	₹7 Cr	₹8 Cr	₹9 Cr	₹8 Cr	₹4 Cr	₹7 Cr	₹10 Cr	₹11 Cr	₹12 Cr	₹13 Cr	₹13 Cr	₹14 Cr	₹78 L	₹3 Cr	₹9 L	₹0	₹50 Cr	₹27 Cr	₹54 Cr	₹38 Cr	₹30 Cr	₹17 Cr	₹22 Cr
₹3 Cr	₹23 Cr	-₹12 Cr	-₹3 Cr	-₹7 Cr	₹19 Cr	₹22 Cr	₹26 Cr	₹28 Cr	₹30 Cr	₹30 Cr	₹20 Cr	₹11 Cr	₹66 Cr	₹7 Cr	-₹3 Cr	-₹14 Cr	-₹4 Cr	-₹11 Cr	-₹17 Cr	-₹28 Cr	-₹3 Cr	-₹45 Cr	-₹24 Cr	-₹23 Cr	-₹39 Cr	-₹28 Cr	-₹26 Cr	-₹38 Cr	-₹8 Cr	₹76 Cr	-₹17 Cr	-₹1 Cr	-₹34 Cr	₹73 Cr	₹14 Cr
₹3 Cr	₹23 Cr	-₹12 Cr	-₹3 Cr	-₹7 Cr	₹19 Cr	₹22 Cr	₹26 Cr	₹28 Cr	₹34 Cr	₹30 Cr	₹20 Cr	₹11 Cr	₹59 Cr	₹7 Cr	-₹3 Cr	-₹14 Cr	-₹5 Cr	-₹14 Cr	₹49 Cr	-₹31 Cr	-₹25 Cr	-₹45 Cr	-₹24 Cr	-₹23 Cr	-₹39 Cr	-₹28 Cr	-₹26 Cr	-₹38 Cr	-₹11 Cr	₹57 Cr	-₹19 Cr	-₹5 Cr	-₹34 Cr	₹49 Cr	₹11 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Secured Loans

Unsecured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Trade Payables

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Miscellaneous Expenses not written off

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Sep 2013	Mar 2012	Mar 2011	Mar 2010	Mar 2009	Mar 2008	Mar 2007	Mar 2006
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹15 Cr	₹15 Cr	₹51 Cr	₹41 Cr	₹41 Cr	₹41 Cr	₹41 Cr	₹89 Cr	₹89 Cr	₹89 Cr	₹89 Cr	₹85 Cr	₹70 Cr	₹70 Cr	₹70 Cr	₹70 Cr	₹70 Cr	₹66 Cr	₹66 Cr	₹65 Cr
₹45 Cr	₹45 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹96,000	₹0
₹1504 Cr	₹1494 Cr	₹1119 Cr	₹648 Cr	₹607 Cr	₹612 Cr	₹725 Cr	-₹793 Cr	-₹881 Cr	-₹477 Cr	-₹40 Cr	₹244 Cr	₹310 Cr	₹1062 Cr	₹999 Cr	₹867 Cr	₹563 Cr	₹599 Cr	₹419 Cr	₹711 Cr
₹1504 Cr	₹1494 Cr	₹1119 Cr	₹648 Cr	₹607 Cr	₹612 Cr	₹725 Cr	-₹793 Cr	-₹881 Cr	-₹477 Cr	-₹40 Cr	₹244 Cr	₹310 Cr	₹1062 Cr	₹999 Cr	₹867 Cr	₹563 Cr	₹599 Cr	₹419 Cr	₹711 Cr
₹1564 Cr	₹1554 Cr	₹1169 Cr	₹689 Cr	₹647 Cr	₹653 Cr	₹766 Cr	-₹704 Cr	-₹792 Cr	-₹388 Cr	₹49 Cr	₹329 Cr	₹380 Cr	₹1132 Cr	₹1069 Cr	₹938 Cr	₹634 Cr	₹665 Cr	₹485 Cr	₹776 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹62 L	₹3 Cr	₹2 Cr	₹0	₹0	₹0	₹0	₹0
₹185 Cr	₹3 L	₹22 L	₹40 Cr	₹111 Cr	₹342 Cr	₹430 Cr	₹1425 Cr	₹1894 Cr	₹2157 Cr	₹2378 Cr	₹2494 Cr	₹902 Cr	₹1074 Cr	₹604 Cr	₹1036 Cr	₹1714 Cr	₹980 Cr	₹707 Cr	₹843 Cr
₹0	₹10 Cr	₹120 Cr	₹109 Cr	₹97 Cr	₹86 Cr	₹74 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹625 Cr	₹902 Cr	₹991 Cr	₹942 Cr	₹202 Cr
-₹29 L	-₹10 L	₹0	₹3 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹46 Cr	₹94 Cr	₹111 Cr	₹157 Cr	₹170 Cr	₹194 Cr	₹203 Cr	₹128 Cr	₹115 Cr	₹92 Cr	₹80 Cr
₹5 Cr	₹4 L	₹37 L	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹42 Cr	₹0	₹0	₹0	₹0	₹0
₹13 Cr	₹5 Cr	₹4 Cr	₹13 Cr	₹11 Cr	₹12 Cr	₹12 Cr	₹8 Cr	₹7 Cr	₹2 Cr	₹4 Cr	₹4 Cr	₹5 Cr	₹8 Cr	₹10 Cr	₹0	₹0	₹0	₹0	₹0
₹203 Cr	₹15 Cr	₹124 Cr	₹165 Cr	₹222 Cr	₹442 Cr	₹519 Cr	₹1436 Cr	₹1905 Cr	₹2205 Cr	₹2475 Cr	₹2609 Cr	₹1064 Cr	₹1252 Cr	₹850 Cr	₹1864 Cr	₹2744 Cr	₹2085 Cr	₹1741 Cr	₹1125 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹347 Cr	₹336 Cr	₹230 Cr	₹174 Cr	₹168 Cr	₹110 Cr	₹102 Cr	₹302 Cr	₹359 Cr	₹425 Cr	₹374 Cr	₹311 Cr	₹597 Cr	₹447 Cr	₹335 Cr	₹318 Cr	₹390 Cr	₹296 Cr	₹235 Cr	₹216 Cr
₹56 Cr	₹27 Cr	₹14 Cr	₹53 Cr	₹47 Cr	₹26 Cr	₹70 Cr	₹1344 Cr	₹958 Cr	₹476 Cr	₹285 Cr	₹113 Cr	₹1053 Cr	₹407 Cr	₹1005 Cr	₹294 Cr	₹369 Cr	₹359 Cr	₹389 Cr	₹23 Cr
₹88 Cr	₹143 Cr	₹14 Cr	₹141 Cr	₹23 Cr	₹3 Cr	₹0	₹695 Cr	₹694 Cr	₹600 Cr	₹634 Cr	₹647 Cr	₹1525 Cr	₹647 Cr	₹490 Cr	₹0	₹0	₹0	₹0	₹0
₹80 L	₹3 Cr	₹2 Cr	₹3 Cr	₹3 Cr	₹4 Cr	₹3 Cr	₹4 Cr	₹1 Cr	₹40 Cr	₹44 Cr	₹52 Cr	₹31 Cr	₹50 Cr	₹159 Cr	₹360 Cr	₹97 Cr	₹78 Cr	₹42 Cr	₹30 Cr
₹491 Cr	₹509 Cr	₹260 Cr	₹372 Cr	₹241 Cr	₹142 Cr	₹175 Cr	₹2346 Cr	₹2013 Cr	₹1541 Cr	₹1338 Cr	₹1123 Cr	₹3206 Cr	₹1551 Cr	₹1989 Cr	₹972 Cr	₹856 Cr	₹734 Cr	₹665 Cr	₹268 Cr
₹2258 Cr	₹2077 Cr	₹1554 Cr	₹1225 Cr	₹1111 Cr	₹1237 Cr	₹1460 Cr	₹3077 Cr	₹3125 Cr	₹3358 Cr	₹3862 Cr	₹4061 Cr	₹4651 Cr	₹3938 Cr	₹3910 Cr	₹3774 Cr	₹4234 Cr	₹3484 Cr	₹2891 Cr	₹2169 Cr
₹25 Cr	₹18 Cr	₹57 Cr	₹42 Cr	₹43 Cr	₹45 Cr	₹0	₹143 Cr	₹162 Cr	₹141 Cr	₹71 Cr	₹107 Cr	₹168 Cr	₹531 Cr	₹322 Cr	₹405 Cr	₹365 Cr	₹385 Cr	₹269 Cr	₹303 Cr
₹301 Cr	₹153 Cr	₹134 Cr	₹331 Cr	₹268 Cr	₹453 Cr	₹566 Cr	₹3230 Cr	₹3202 Cr	₹3106 Cr	₹3215 Cr	₹3211 Cr	₹3204 Cr	₹2005 Cr	₹2079 Cr	₹1661 Cr	₹2616 Cr	₹1971 Cr	₹1649 Cr	₹1045 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹1517 Cr	₹1499 Cr	₹1301 Cr	₹1221 Cr	₹1176 Cr	₹1176 Cr	₹1247 Cr	₹1520 Cr	₹1519 Cr	₹3006 Cr	₹3006 Cr	₹3002 Cr	₹3772 Cr	₹3090 Cr	₹2614 Cr	₹2345 Cr	₹2696 Cr	₹2098 Cr	₹1563 Cr	₹1364 Cr
₹825 Cr	₹791 Cr	₹681 Cr	₹647 Cr	₹593 Cr	₹506 Cr	₹389 Cr	₹263 Cr	₹133 Cr	₹1509 Cr	₹1369 Cr	₹1207 Cr	₹1189 Cr	₹1016 Cr	₹872 Cr	₹741 Cr	₹688 Cr	₹558 Cr	₹458 Cr	₹374 Cr
₹692 Cr	₹708 Cr	₹620 Cr	₹573 Cr	₹584 Cr	₹670 Cr	₹858 Cr	₹1256 Cr	₹1386 Cr	₹1497 Cr	₹1637 Cr	₹1795 Cr	₹2584 Cr	₹2074 Cr	₹1742 Cr	₹1603 Cr	₹2008 Cr	₹1540 Cr	₹1105 Cr	₹990 Cr
₹341 Cr	₹64 Cr	₹16 Cr	₹46 Cr	₹10 Cr	₹7 Cr	₹15 Cr	₹264 Cr	₹257 Cr	₹274 Cr	₹265 Cr	₹267 Cr	₹332 Cr	₹329 Cr	₹322 Cr	₹469 Cr	₹547 Cr	₹620 Cr	₹553 Cr	₹270 Cr
₹67 Cr	₹60 Cr	₹46 Cr	₹44 Cr	₹45 Cr	₹40 L	₹34 L	₹47 L	₹1 Cr	₹96 L	₹81 L	₹81 L	₹95 L	₹81 L	₹81 L	₹0	₹0	₹0	₹0	₹0
₹67 Cr	₹60 Cr	₹46 Cr	₹44 Cr	₹45 Cr	₹40 L	₹34 L	₹47 L	₹1 Cr	₹96 L	₹81 L	₹81 L	₹95 L	₹81 L	₹81 L	₹0	₹0	₹0	₹0	₹0
₹156 Cr	₹131 Cr	₹66 Cr	₹60 Cr	₹74 Cr	₹9 Cr	₹7 Cr	₹765 Cr	₹778 Cr	₹687 Cr	₹681 Cr	₹683 Cr	₹577 Cr	₹221 Cr	₹296 Cr	₹0	₹0	₹0	₹0	₹0
₹2 L	₹2 L	₹2 L	₹0	₹74,000	₹1 L	₹0	₹10 Cr	₹10 Cr	₹6 Cr	₹12 Cr	₹23 Cr	₹28 Cr	₹37 Cr	₹13 Cr	₹0	₹0	₹0	₹0	₹0
₹1329 Cr	₹980 Cr	₹763 Cr	₹724 Cr	₹713 Cr	₹687 Cr	₹891 Cr	₹2310 Cr	₹2446 Cr	₹2479 Cr	₹2611 Cr	₹2783 Cr	₹3550 Cr	₹2685 Cr	₹2384 Cr	₹2072 Cr	₹2554 Cr	₹2160 Cr	₹1658 Cr	₹1261 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹0	₹0	₹0	₹0	₹0	₹15 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹81 L	₹81 L	₹81 L	₹8 L	₹8 L
₹372 Cr	₹457 Cr	₹264 Cr	₹229 Cr	₹173 Cr	₹153 Cr	₹142 Cr	₹170 Cr	₹194 Cr	₹211 Cr	₹242 Cr	₹252 Cr	₹506 Cr	₹669 Cr	₹618 Cr	₹423 Cr	₹768 Cr	₹649 Cr	₹612 Cr	₹448 Cr
₹381 Cr	₹353 Cr	₹196 Cr	₹215 Cr	₹171 Cr	₹136 Cr	₹68 Cr	₹120 Cr	₹120 Cr	₹203 Cr	₹310 Cr	₹257 Cr	₹179 Cr	₹113 Cr	₹513 Cr	₹737 Cr	₹673 Cr	₹538 Cr	₹383 Cr	₹349 Cr
₹84 Cr	₹201 Cr	₹267 Cr	₹31 Cr	₹8 Cr	₹20 Cr	₹174 Cr	₹326 Cr	₹306 Cr	₹257 Cr	₹315 Cr	₹391 Cr	₹23 Cr	₹177 Cr	₹201 Cr	₹335 Cr	₹53 Cr	₹31 Cr	₹119 Cr	₹16 Cr
₹17 Cr	₹11 Cr	₹7 Cr	₹4 Cr	₹13 Cr	₹10 Cr	₹22 Cr	₹12 Cr	₹20 Cr	₹9 Cr	₹117 Cr	₹80 L	₹14 Cr	₹16 Cr	₹9 Cr	₹4 Cr	₹5 Cr	₹4 Cr	₹3 Cr	₹2 Cr
₹75 Cr	₹76 Cr	₹57 Cr	₹23 Cr	₹20 Cr	₹96 Cr	₹164 Cr	₹140 Cr	₹40 Cr	₹198 Cr	₹268 Cr	₹378 Cr	₹378 Cr	₹278 Cr	₹185 Cr	₹201 Cr	₹97 Cr	₹102 Cr	₹116 Cr	₹93 Cr
₹929 Cr	₹1097 Cr	₹791 Cr	₹501 Cr	₹384 Cr	₹429 Cr	₹569 Cr	₹767 Cr	₹679 Cr	₹879 Cr	₹1251 Cr	₹1278 Cr	₹1101 Cr	₹1253 Cr	₹1526 Cr	₹1701 Cr	₹1596 Cr	₹1324 Cr	₹1233 Cr	₹908 Cr
₹438 Cr	₹589 Cr	₹531 Cr	₹129 Cr	₹144 Cr	₹287 Cr	₹394 Cr	-₹1578 Cr	-₹1334 Cr	-₹662 Cr	-₹86 Cr	₹155 Cr	-₹2105 Cr	-₹298 Cr	-₹463 Cr	₹729 Cr	₹740 Cr	₹590 Cr	₹568 Cr	₹640 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹84 Cr	₹0	₹0	₹0
₹2258 Cr	₹2077 Cr	₹1554 Cr	₹1225 Cr	₹1111 Cr	₹1237 Cr	₹1460 Cr	₹3077 Cr	₹3125 Cr	₹3358 Cr	₹3862 Cr	₹4061 Cr	₹4651 Cr	₹3938 Cr	₹3910 Cr	₹3774 Cr	₹4234 Cr	₹3484 Cr	₹2891 Cr	₹2169 Cr
₹993	₹987	₹231	₹169	₹159	₹160	₹188	-₹79	-₹89	-₹44	₹6	₹39	₹54	₹161	₹152	₹133	₹78	₹101	₹74	₹120
₹993	₹987	₹231	₹169	₹159	₹160	₹188	-₹79	-₹89	-₹44	₹6	₹39	₹54	₹161	₹152	₹133	₹78	₹101	₹74	₹120

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Sep 2013	Mar 2012	Mar 2011	Mar 2010	Mar 2009	Mar 2008	Mar 2007
₹10 Cr	₹122 Cr	₹89 Cr	₹46 Cr	-₹2 Cr	-₹117 Cr	-₹131 Cr	₹69 Cr	-₹399 Cr	-₹452 Cr	-₹296 Cr	-₹243 Cr	-₹573 Cr	₹75 Cr	₹172 Cr	₹470 Cr	-₹34 Cr	₹229 Cr	₹93 Cr
₹42 Cr	₹40 Cr	₹44 Cr	₹51 Cr	₹37 Cr	₹172 Cr	₹140 Cr	₹57 Cr	₹453 Cr	₹582 Cr	₹490 Cr	₹1006 Cr	₹661 Cr	₹334 Cr	₹215 Cr	-₹557 Cr	₹200 Cr	₹132 Cr	₹189 Cr
₹71 Cr	-₹95 Cr	-₹8 Cr	-₹79 Cr	₹60 Cr	-₹37 Cr	₹62 Cr	-₹110 Cr	-₹38 Cr	₹187 Cr	₹18 Cr	-₹669 Cr	₹79 Cr	₹357 Cr	₹7 Cr	₹119 Cr	-₹117 Cr	-₹118 Cr	-₹184 Cr
₹123 Cr	₹67 Cr	₹125 Cr	₹19 Cr	₹94 Cr	₹19 Cr	₹70 Cr	₹16 Cr	₹16 Cr	₹317 Cr	₹212 Cr	₹94 Cr	₹168 Cr	₹766 Cr	₹393 Cr	₹32 Cr	₹49 Cr	₹243 Cr	₹97 Cr
₹126 Cr	₹51 Cr	₹126 Cr	₹18 Cr	₹92 Cr	₹24 Cr	₹81 Cr	₹12 Cr	₹9 Cr	₹317 Cr	₹212 Cr	-₹369 Cr	₹168 Cr	₹737 Cr	₹332 Cr	-₹34 Cr	₹46 Cr	₹210 Cr	₹96 Cr
-₹277 Cr	-₹36 Cr	-₹312 Cr	-₹31 Cr	₹113 Cr	₹67 Cr	₹167 Cr	₹45 Cr	-₹28 Cr	-₹9 Cr	-₹1 Cr	₹1334 Cr	-₹986 Cr	-₹293 Cr	-₹367 Cr	₹1413 Cr	-₹477 Cr	-₹545 Cr	-₹477 Cr
₹137 Cr	₹2 Cr	₹167 Cr	₹31 Cr	-₹217 Cr	-₹165 Cr	-₹250 Cr	-₹30 L	₹33 Cr	-₹366 Cr	-₹286 Cr	-₹597 Cr	₹664 Cr	-₹480 Cr	-₹78 Cr	-₹1077 Cr	₹431 Cr	₹247 Cr	₹485 Cr
-₹14 Cr	₹17 Cr	-₹19 Cr	₹18 Cr	-₹11 Cr	-₹74 Cr	-₹2 Cr	₹57 Cr	₹15 Cr	-₹58 Cr	-₹76 Cr	₹367 Cr	-₹153 Cr	-₹36 Cr	-₹113 Cr	₹302 Cr	₹2 L	-₹88 Cr	₹104 Cr
₹21 Cr	₹4 Cr	₹23 Cr	₹4 Cr	₹16 Cr	₹90 Cr	₹92 Cr	₹35 Cr	₹21 Cr	₹315 Cr	₹391 Cr	₹23 Cr	₹177 Cr	₹213 Cr	₹326 Cr	₹24 Cr	₹24 Cr	₹112 Cr	₹8 Cr
₹7 Cr	₹21 Cr	₹4 Cr	₹23 Cr	₹4 Cr	₹16 Cr	₹90 Cr	₹92 Cr	₹35 Cr	₹257 Cr	₹315 Cr	₹391 Cr	₹23 Cr	₹177 Cr	₹213 Cr	₹326 Cr	₹24 Cr	₹24 Cr	₹112 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Orchid Pharma Share Price

945.25-14.70 (-1.53%)

+29.79% past 1 Year

Shareholding summary

Promoters

69.84%

FII

0.8%

DII

0.82%

19.93%

Others

8.61%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
69.84%	69.84%	69.84%	69.84%	69.84%	69.84%
0.80%	0.87%	1.17%	1.56%	1.39%	2.69%
0.82%	0.81%	1.38%	1.00%	0.85%	1.31%
19.93%	19.43%	18.01%	18.04%	18.58%	18.79%
8.61%	9.05%	9.60%	9.56%	9.34%	7.37%

Bulk & block deals

Name

Uti Mutual Fund

Dhanuka Laboratories Limited

Polaris Banyan Holding Private Ltd

Adurjee And Bros Pvt Ltd

Serum Institute Of India Private Limited

Fortune Intercontinental Pvt Ltd

Serum Institute Of India Private Limited

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
30 May 2025	Purchase	22.55 Cr	₹615.37	3.67 L	Bulk	0.612016	NSE
28 Nov 2023	Purchase	25.41 Cr	₹571	4.45 L	Bulk	0.743088	BSE
28 Nov 2023	Sell	74.27 Cr	₹571.28	13 L	Bulk	2.17082	BSE
10 Jan 2018	Purchase	1.27 Cr	₹24.02	5.29 L	Bulk	0.883357	NSE
04 Jan 2018	Sell	1.45 Cr	₹21.10	6.85 L	Bulk	1.143668	NSE
03 Jan 2018	Sell	2.64 Cr	₹20.10	13.12 L	Bulk	2.191693	NSE
03 Jan 2018	Sell	1.32 Cr	₹20.10	6.58 L	Bulk	1.098954	NSE
03 Jan 2018	Sell	95.41 L	₹20.30	4.70 L	Bulk	0.784835	BSE
19 Dec 2017	Sell	1.37 Cr	₹19.37	7.06 L	Bulk	1.178341	NSE
18 Dec 2017	Sell	1.39 Cr	₹18.55	7.50 L	Bulk	1.252396	NSE

Insider trading & SAST

Client name

R Vijayalakshmi

Orchid Health Care Pvt Ltd

R Vijayalakshmi

K Raghavendra Rao

R Vijayalakshmi

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
24 Dec 2024	Promoter	Pledge	—	—	—	2 L	31 Jan 2014	Creation	43,83,400	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	7.45 L	31 Mar 2014	Creation	35,95,000	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	4.38 L	31 Mar 2014	Release	39,45,400	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	2.96 L	31 Mar 2014	Creation	56,06,000	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	5.50 L	31 Mar 2014	Release	53,10,000	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	9 L	15 May 2014 - 21 May 2014	Creation	48,45,400	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	2 L	29 May 2014	Release	46,45,400	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	4 L	07 Jul 2014	Release	42,45,400	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	2 L	28 Jul 2014	Release	40,45,400	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	7 L	26 Nov 2014 - 01 Dec 2014	Creation	61,26,155	SAST	Reg31	—

Orchid Pharma Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Orchid Pharma Share Price

Orchid Pharma Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Orchid Pharma Share Price

Orchid Pharma Share Price

Oscillators

Moving averages

Orchid Pharma Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Orchid Pharma Share Price

Corporate Actions

Company details

Orchid Pharma Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Orchid Pharma Share Price

News

Orchid Pharma Purchases Kancheepuram Land And Ends DBS Bank Lease

Orchid Pharma to commence 7-ACA plant operations by March 2027

Orchid Pharma inks exclusive Exblifep licensing deal with Russian firm Pharmasyntez

Orchid Pharma projects significant global sales potential for key antibiotic combo

Orchid Pharma nears US licensing deal for novel antibiotic candidate

Orchid Pharma gains NCLT nod for merger with Dhanuka Lab to scale operations

Orchid Pharma informs about investor presentation

Orchid Pharma reports Profit after tax of 30.60 Crores, in the March 2026 quarter

Orchid Pharma Q4 EBITDA declines year-on-year with lower operating margin performance

Orchid Pharma Q4 FY earnings: flat revenue, modest profit growth YoY

NCLT Rejects DBS Bank's Lease Rent Claim Against Orchid Pharma in CIRP Proceedings

Orchid Pharma Q3 FY2026 Results: Sharp EBITDA Decline and Consolidated Loss

Orchid Pharma Q3 FY2025 Consolidated Net Loss of Rs 12.60 Crores vs YoY Profit.

Orchid Pharma reports Profit after tax of Rs -5.83 Crores, in the December 2025 quarter

Orchid Pharma aims for FY26 revenue growth with capacity, product pipeline, and Chennai plant commissioning.

Orchid Pharma reports Profit after tax of 2.23 Crores, in the September 2025 quarter

Orchid Pharma reports Q2 FY25 earnings with EBITDA of Rs 37.5 crores; revenue rose 12% YoY.

Orchid Pharma reports Q2 FY25 consolidated net loss of Rs 5.70 crores versus Rs 25.60 crores profit year-on-year.

Orchid Pharma: Co Aims To Cut Costs And Maintain Margins Due To Weak Sales; Using Api Portfolio, Export Chances, And Efficiency To Boost Medium-Term Revenue And Profit Growth. ??

Orchid Pharma: Q1 Ebitda 14.20 Crores Rupees Vs 32.50 Crores (Yoy) || Q1 Ebitda Margin 8.19% Vs 13.29% (Yoy)

Orchid Pharma Ltd Share Price Today

Orchid Pharma Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator